- Dr. Majed Halwani
- Ext. (84) 94433
- About Head
The presence of Nanotechnology, alongside other research areas, plays an important role in advancing the medical field. The Nanomedicine group focuses on applications of nanotechnology in a medical/ clinical context. The group gathers distinguished researchers with different backgrounds to conduct research, share ideas and discuss prospects of the field.
The projects that the Nanomedicine group leads as a contribution to medical research include:
Improving point-of-care diagnostics to allow early intervention and a better patient outcome.
Developing novel drug delivery systems for chemotherapy, vaccines, gene delivery and infectious diseases.
Utilizing nanoparticles and advanced materials for tissue repair and regeneration.
Our main goal is to translate Nanomedicine research from bench to bedside by carrying it from laboratory experiments through clinical trials to clinical patient applications. It is also carried out with many collaborations with nationally and internationally recognized institutes/affiliates.
Dr. Halwani obtained Bachelor of Science in Biochemistry from King Abdulaziz University, Jeddah, Saudi Arabia (1997). He served as Laboratory Specialist in different laboratory sections of in MOH hospitals until 2002. He obtained a scholarship from MOH to pursue his Master and PhD in Biomolecular Sciences (Drug and Vaccine Delivery Systems) at Laurentian University, Sudbury, Canada (2010). Since then, he served as Assistance Director for Planning and Development at Jeddah Poison Control Center until 2013, where he started his research activity at MOH and successfully received his first grant form KACST for developing Nanotechnology drugs for treating Cancer. In 2013, he was recruited by Infectious Disease Research leader in KAIMRC to join the team to develop antibiotics by Nanotechnology, where he successfully filed his first patent, in 2014, through United States Patent and Trademark Office regarding his first antibiotic developed by Nanotechnology in KAIMRC. In 2015, he was transferred to join the initiative of establishing the Nanomedicine Department at KAIMRC where it was called Nanomedicine Unit. In 2016, he successfully filed his second patent through United States Patent and Trademark Office regarding his first anticancer drug developed by Nanotechnology in KAIMRC and received the official registration of this patent in early 2017. As then, he received the honor recognition of KAMIRC reward of intellectual property prize from His Highness Prince Khalid bin Ayyaf, National Guard Minister. Currently, he is the Head of Nanomedicine Department and also he is a member of many scientific committees. He has been active in various researches and peer- reviewed journals in the field of Nanotechnology.
- Hasan, M.N., Choudhry, H., Razvi, S.S., Moselhy, S.S., Kumosani, T.A., Zamzami, M.A., Omran, Z., Halwani, M.A., Al-Babili, S., Abualnaja, K.O. and Al-Malki, A.L., 2018. Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells. Bioorganic & medicinal chemistry letters.
- Alhariri, M., Majrashi, M.A., Bahkali, A.H., Almajed, F.S., Azghani, A.O., Khiyami, M.A., Alyamani, E.J., Aljohani, S.M. and Halwani, M.A., 2017. Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities. International journal of nanomedicine, 12, p.6949.
- Chinnappan, Raja, Saleh AlAmer, Shimaa Eissa, Anas Abdel Rahamn, Khalid M. Abu Salah, and Mohammed Zourob. “Fluorometric graphene oxide-based detection of Salmonella enteritis using a truncated DNA aptamer.” Microchimica Acta185, no. 1 (2018): 61.
- Eissa, S., Alshehri, N., Rahman, A.M.A., Dasouki, M., Salah, K.M.A. and Zourob, M., 2018. Electrochemical immunosensors for the detection of survival motor neuron (SMN) protein using different carbon nanomaterials-modified electrodes. Biosensors and Bioelectronics, 101, pp.282-289.
- Alsharaeh, E.H., Bora, T., Soliman, A., Ahmed, F., Bharath, G., Ghoniem, M.G., Abu-Salah, K.M. and Dutta, J., 2017. Sol-Gel-Assisted Microwave-Derived Synthesis of Anatase Ag/TiO2/GO Nanohybrids toward Efficient Visible Light Phenol Degradation. Catalysts, 7(5), p.133.
- Asem, H., Zhao, Y., Ye, F., Barrefelt, Å., Abedi-Valugerdi, M., El-Sayed, R., El-Serafi, I., Abu-Salah, K.M., Hamm, J., Muhammed, M. and Hassan, M., 2016. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging. Journal of nanobiotechnology, 14(1), p.82.
- Halwani, M., Balkhy, H.H., Khiyami, M.A. and Omri, A., 2015. 130 Antimicrobial activity of liposomal β-glycan against Pseudomonas aeruginosa isolated from cystic fibrosis patients. Journal of Cystic Fibrosis, 14, p.S91.
- Aisha, A.F., Abdulmajid, A.M.S., Ismail, Z., Alrokayan, S.A. and Abu-Salah, K.M., 2015. Development of polymeric nanoparticles of Garcinia mangostana xanthones in eudragit RL100/RS100 for anti-colon cancer drug delivery. Journal of Nanomaterials, 16(1), p.385.
- Abu-Salah, K.M., Zourob, M.M., Mouffouk, F., Alrokayan, S.A., Alaamery, M.A. and Ansari, A.A., 2015. DNA-based nanobiosensors as an emerging platform for detection of disease. Sensors, 15(6), pp.14539-14568.
- Solleti, V.S., Alhariri, M., Halwani, M. and Omri, A., 2014. Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 70(3), pp.784-796.
- Omri, A. and Halwani, M., 2014. WS2. 1 Liposomal clarithromycin effect on bacterial adhesion to epithelia of cystic fibrosis patients. Journal of Cystic Fibrosis, 13, p.S3.
- Halwani, M.A.S. and Alhariri, M.A., KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER, King Saud Bin Abdulaziz University For Health Sciences and NATIONAL GUARD HEALTH AFFAIRS, 2017. Therapeutic liposome and method of treating a subject having cancer. U.S. Patent 9,655,847.
- Halwani, M.A. and Balkhy, H.H., King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University For Health Sciences and National Guard Health Affairs, 2016. Nano-liposomal aminoglycoside-thymoquinone formulations. U.S. Patent Application 14/513,114.